Shattuck Labs CMO sells 30K shares

Shattuck Labs, Inc. chief medical officer Arundathy N. Pandite reported an open-market sale of 30,000 shares of common stock.

Rhea-AI Filing Summary

Shattuck Labs, Inc. chief medical officer Arundathy N. Pandite reported an open-market sale of 30,000 shares of common stock. The shares were sold at a weighted average price of $6.61 per share, in multiple trades between $6.41 and $7.03. Following the transaction, she directly holds 166,219 shares. The sale was effected under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2026.

Insider Trade Summary 10b5-1

Net Seller: 30,000 shares

Net Sell 1 txn

Insider Pandite Arundathy N.

Role Chief Medical Officer

Sold 30,000 shs ($198K)

Type	Security	Shares	Price	Value
Sale	Common Stock	30,000	$6.61	$198K

Holdings After Transaction: Common Stock — 166,219 shares (Direct)

Footnotes (2)

1. F1. Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026.
2. F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.41 to $7.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range

Key Figures

Shares sold: 30,000 shares Weighted average sale price: $6.61 per share Sale price range: $6.41–$7.03 per share +2 more

5 metrics

Shares sold 30,000 shares Open-market sale of common stock on May 12, 2026

Weighted average sale price $6.61 per share Average price across multiple sale transactions

Sale price range $6.41–$7.03 per share Range of prices for individual trades included in the sale

Shares held after transaction 166,219 shares Total common shares beneficially owned following the sale

Trading plan adoption date February 2, 2026 Date Rule 10b5-1 trading plan was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, non-derivative

4 terms

Rule 10b5-1 trading plan regulatory

"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above is a weighted average price. The shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

""transaction_type": "non-derivative""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Shattuck Labs (STTK) report for its CMO?

Shattuck Labs reported that chief medical officer Arundathy N. Pandite sold 30,000 shares of common stock. The Form 4 shows this was an open-market sale executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2026.

How many Shattuck Labs (STTK) shares did the CMO sell and at what prices?

The chief medical officer sold 30,000 shares of Shattuck Labs common stock. The reported weighted average sale price was $6.61 per share, with individual transactions executed in a price range from $6.41 to $7.03 per share, inclusive.

How many Shattuck Labs (STTK) shares does the CMO hold after the sale?

After the reported sale, the chief medical officer directly holds 166,219 shares of Shattuck Labs common stock. This figure comes from the Form 4 disclosure of total shares beneficially owned following completion of the 30,000-share open-market transaction.

Was the Shattuck Labs (STTK) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state the sale was effected pursuant to a Rule 10b5-1 trading plan. That trading plan was adopted by the reporting person on February 2, 2026, indicating the transactions were pre-arranged rather than newly decided at the trade date.

What type of transaction did the Shattuck Labs (STTK) Form 4 disclose?

The filing disclosed an open-market sale of common stock by the chief medical officer. It is classified with transaction code “S,” described as a sale in an open market or private transaction, and involves non-derivative securities rather than options or other derivatives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pandite Arundathy N.

(Last) (First) (Middle)

C/O SHATTUCK LABS, INC.

500 W. 5TH STREET, SUITE 1200

(Street)

AUSTIN TEXAS 78701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/12/2026		S(1)		30,000	D	$6.61(2)	166,219	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.41 to $7.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range

	/s/ Andrew R. Neill, Attorney-in-fact for Arundathy N. Pandite	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)